---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: IL-23 inhibitors"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: IL-23 inhibitors. Topics: Biologics guideline: recommendations for guselkumab and tildrakizumab; Guselkumab: FDA-approved indication, dosage, and week 16 outcomes in Trials PsO1 and PsO2; Risankizumab: FDA-approved indication, dosage, and week 16 and week 52 outcomes in PsO-1 and PsO-2; Tildrakizumab: FDA-approved indication, dosage, and week 12 outcomes in Trials 2 and 3; 3 further topics. 7 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/il-23-inhibitors"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: IL-23 inhibitors

<a id="heading-2.2.2.1.10"></a>

## 2.2.2.1.10 IL-23 Inhibitors

<a id="topic-2.2.2.1.10-1"></a>

### Biologics guideline: recommendations for guselkumab and tildrakizumab

> “Guselkumab is recommended as a monotherapy treatment option for use in adult patients with moderate-to-severe plaque psoriasis”
> “The recommended dose of guselkumab is 100 mg by self-administered subcutaneous injection at wk 0, wk 4, and every 8 wk thereafter”
> “Tildrakizumab is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.10-2"></a>

### Guselkumab: FDA-approved indication, dosage, and week 16 outcomes in Trials PsO1 and PsO2

> “TREMFYA is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy.”
> “Administer TREMFYA by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.”

Source: [Janssen TREMFYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)

| Outcome at Week 16, n (%) | Trial PsO1 placebo (N=174) | Trial PsO1 TREMFYA (N=329) | Trial PsO2 placebo (N=248) | Trial PsO2 TREMFYA (N=496) |
| --- | --- | --- | --- | --- |
| IGA response of 0/1 | “12 (7)” | “280 (85)” | “21 (8)” | “417 (84)” |
| PASI 90 response | “5 (3)” | “241 (73)” | “6 (2)” | “347 (70)” |

Source: [Janssen TREMFYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)

<a id="topic-2.2.2.1.10-3"></a>

### Risankizumab: FDA-approved indication, dosage, and week 16 and week 52 outcomes in PsO-1 and PsO-2

> “SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage for adults is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter [see Dosage and Administration (2.7)].”
> “In PsO-1 and PsO-2 at Week 52, subjects receiving SKYRIZI achieved sPGA 0 (58% and 60%, respectively), PASI 90 (82% and 81%, respectively), and PASI 100 (56% and 60%, respectively).”

Source: [AbbVie SKYRIZI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

| Outcome at Week 16, n (%) | PsO-1 SKYRIZI (N=304) | PsO-1 placebo (N=102) | PsO-2 SKYRIZI (N=294) | PsO-2 placebo (N=98) |
| --- | --- | --- | --- | --- |
| sPGA 0 or 1 | “267 (88)” | “8 (8)” | “246 (84)” | “5 (5)” |
| PASI 90 | “229 (75)” | “5 (5)” | “220 (75)” | “2 (2)” |
| PASI 100 | “109 (36)” | “0 (0)” | “149 (51)” | “2 (2)” |

Source: [AbbVie SKYRIZI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

<a id="topic-2.2.2.1.10-4"></a>

### Tildrakizumab: FDA-approved indication, dosage, and week 12 outcomes in Trials 2 and 3

> “ILUMYA® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage in adult patients with moderate-to-severe plaque psoriasis is 100 mg at Weeks 0, 4, and every 12 weeks thereafter.”

Source: [Sun Pharma ILUMYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761067s031lbl.pdf)

| Outcome at Week 12, n (%) | Trial 2 ILUMYA 100 mg (N=309) | Trial 2 placebo (N=154) | Trial 3 ILUMYA 100 mg (N=307) | Trial 3 placebo (N=156) |
| --- | --- | --- | --- | --- |
| PGA of 0 or 1 | “179 (58)” | “11 (7)” | “168 (55)” | “7 (4)” |
| PASI 75 | “197 (64)” | “9 (6)” | “188 (61)” | “9 (6)” |
| PASI 90 | “107 (35)” | “4 (3)” | “119 (39)” | “2 (1)” |

Source: [Sun Pharma ILUMYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761067s031lbl.pdf)

<a id="topic-2.2.2.1.10-5"></a>

### Decision aid: IL-23 inhibitors

| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
| --- | --- | --- |
| Guselkumab | “44%” | “85–90% chance” |
| Risankizumab | “51%” | “Not known at present” |
| Tildrakizumab | “32%” | “Not known at present” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.1.10-6"></a>

### Network meta-analyses: anti-IL-23 agents, adverse events, and short-term and long-term PASI 90

> “Placebo had the highest SUCRA (SUCRA 93.9) at class‐level for all adverse events, followed by anti‐IL23 (versus placebo: RR 1.01, 95% CI 0.95 to 1.06; SUCRA = 89.9), anti‐TNF agents (versus placebo: RR 1.08, 95% CI 1.03 to 1.13; SUCRA = 61.3), and anti‐IL12/23 (versus placebo: RR 1.08, 95% CI 1.01 to 1.14; SUCRA = 60.8).”
> “At class level, all treatment classes showed evidence of a higher risk of adverse events compared to placebo, except for anti‐IL23.”
> “guselkumab was more effective than adalimumab in reaching PASI 90 at 52 weeks (RR 1.59, 95% CI 1.40 to 1.81)”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

> “At weeks 44 to 60, the treatments with the highest PASI 90 rates were risankizumab-rzaa (79.4%, 95% CI, 75.5%-82.9%), guselkumab (76.5%; 95% CI, 72.1%-80.5%), brodalumab (74.0%; 95% CI, 69.3%-78.1%), and ixekizumab (73.9%; 95% CI, 69.9%-77.5%).”

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
| --- | --- | --- | --- |
| Risankizumab-rzaa, 150 mg | “89.2 (86.9-91.3)” | “71.6 (67.5-75.4)” | “40.4 (35.9-45.0)” |
| Guselkumab, 100 mg | “86.8 (83.8-89.4)” | “67.3 (62.5-71.9)” | “35.7 (30.9-40.7)” |
| Tildrakizumab-asmn, 100 mg | “62.9 (57.3-68.4)” | “36.8 (31.4-42.5)” | “12.5 (9.7-15.8)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

<a id="topic-2.2.2.1.10-7"></a>

### Drug survival and switching risk with IL-23 inhibitors compared with other biologics

> “Among 19,034 treatment courses (median follow‐up: 2.3 years), treatments included adalimumab (tumour necrosis factor‐alpha (TNF‐a) inhibitor, n = 6,815), ustekinumab (IL‐12/23p40 inhibitor, n = 5,639), secukinumab (IL‐17A inhibitor, n = 3,051), ixekizumab (IL‐17A inhibitor, n = 1,072), brodalumab (n = 367), guselkumab (IL‐23p19 inhibitor, n = 1,258) and risankizumab (n = 832).”
> “Guselkumab and risankizumab had the highest adjusted survival times (years [interquartile ranges]) for effectiveness (1.93 [1.91–1.95] and 1.93 [1.90–1.96], respectively).”

Source: [Motedayen Aval et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12466084/)

> “IL-23 inhibitors were associated with the lowest risk of switching compared with TNF, IL-17, and IL-12/23 inhibitors over 24 months (p < 0.0001).”
> “Switch rates varied between specific biologics, with the lowest switch rates observed for patients treated with risankizumab at 8.5% followed by guselkumab at 15.7% over 24 months.”

Source: [Armstrong et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37154473/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
